U.S. court imposes temporary sales ban on Dr Reddy's generic Nexium

Reuters Health Information: U.S. court imposes temporary sales ban on Dr Reddy's generic Nexium

U.S. court imposes temporary sales ban on Dr Reddy's generic Nexium

Last Updated: 2015-11-10

By Reuters Staff

MUMBAI (Reuters) - Dr Reddy's Laboratories Ltd , India's second-largest drugmaker by sales, said on Tuesday it had been temporarily barred by a U.S. court from selling its generic form of blockbuster heartburn drug Nexium (esomeprazole) in the United States.

The order was passed by the U.S. district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion objecting to the use of the color purple in the Dr Reddy's copycat product, the Indian firm said in a statement.

The temporary restraining order has been imposed "with immediate effect on sales, delivery, transfer, or other disposition" of Dr Reddy's generic Nexium, the company said.

Dr Reddy's launched its generic Nexium in September after weeks of delay, as it had to shift production to a different plant after the U.S. Food and Drug Administration found quality control lapses at the original site.

The U.S. court order is pending a further hearing or trial, and the court has asked both companies to suggest the next course of action, Dr Reddy's said.

Dr Reddy's is evaluating all options to resolve the issue as soon as possible, it said.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.